Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Enanta Pharmaceuticals (ENTA) Receivables Refunds (2020 - 2025)

Enanta Pharmaceuticals filings provide 6 years of Receivables Refunds readings, the most recent being $24000.0 for Q2 2025.

  • On a quarterly basis, Receivables Refunds fell 99.93% to $24000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $24000.0, a 99.93% decrease, with the full-year FY2024 number at $32.0 million, up 3.21% from a year prior.
  • Receivables Refunds hit $24000.0 in Q2 2025 for Enanta Pharmaceuticals, down from $33.8 million in the prior quarter.
  • In the past five years, Receivables Refunds ranged from a high of $37.3 million in Q3 2021 to a low of $24000.0 in Q2 2025.
  • Median Receivables Refunds over the past 5 years was $30.6 million (2021), compared with a mean of $28.9 million.
  • Biggest five-year swings in Receivables Refunds: surged 185.68% in 2021 and later tumbled 99.93% in 2025.
  • Enanta Pharmaceuticals' Receivables Refunds stood at $28.8 million in 2021, then dropped by 0.17% to $28.7 million in 2022, then increased by 10.56% to $31.7 million in 2023, then increased by 2.24% to $32.4 million in 2024, then plummeted by 99.93% to $24000.0 in 2025.
  • The last three reported values for Receivables Refunds were $24000.0 (Q2 2025), $33.8 million (Q1 2025), and $32.4 million (Q4 2024) per Business Quant data.